Lung Cancer: Making the Turn to Hope
“It wasn’t that long ago when patients diagnosed with lung cancer were given little to no hope. But that has changed — drastically.
Research is advancing rapidly.
Treatments have improved.
Patients are living longer.”
Lung cancer: Immunotherapy combined with chemotherapy may improve quality of life in hard-to-treat cases
“The phase 3 EMPOWER-Lung 3 clinical trial had previously shown that cemiplimab in combination with chemotherapy is more effective than chemotherapy alone in enhancing survival outcomes in individuals with advanced non-small cell lung cancer.”
Clinical Updates for the Management of Lung Cancer Brain Metastases
“Nearly half of all brain tumors are associated with an underlying cancer diagnosis, and lung cancer is one of the most common of these. As improved cancer therapies are helping patients live longer, the safe and effective management of lung cancer brain metastases is coming to the fore. The goals we always keep in mind in these cases are to extend survival, prevent neurological dysfunction and improve quality of life. This article briefly reviews the progress made toward these goals made in recent years.”
Significant Weight Loss Associated With Incident Lung Cancer Diagnosis
“Significant weight loss may be associated with incident lung cancer, according to an analysis of electronic health records (EHR) from University of Washington Medicine (UWM) that was published in JAMA Network Open. Patients in the case-control study who experienced 10% to 50% weight loss had a 2-times higher likelihood of being diagnosed with lung cancer.”
Bristol_Myers says FDA has accepted its non-small lung cancer treatment repotrectinib for priority review
“Bristol Myers Squibb Co. said Tuesday the U.S. Food and Drug Administration has accepted for priority review its application for repotrectinib as a treatment for patients with certain kinds of non-small cell lung cancer. Repotrectinib was the lead experimental drug of Turning Point Therapeutics, which Bristol Myers acquired for $3.8 billion in June of 2022.”
Severe Asthma and Lung Cancer: What’s the Link?
“May 22, 2023 – Did you know that cutting-edge research is highlighting the link between heavily symptomatic asthma and lung cancer?”
UChicago Medicine introduces groundbreaking, next-generation robotic technology to combat early lung cancer
“The University of Chicago Medicine is the first U.S. hospital to use new, state-of-the-art robotic technology for bronchoscopies that will improve early detection of lung cancer.”
Phase 3 SAPPHIRE Trial of Sitravatinib Misses Primary End Point in NSCLC
“The phase 3 SAPPHIRE trial (NCT00231270) of sitravatinib (MGCD516) in combination with nivolumab (Opdivo) vs docetaxel did not meet its primary end point of overall survival (OS) at the final analysis in patients with second- or third-line advanced non-squamous non–small cell lung cancer (NSCLC) who progressed on prior therapy with chemotherapy and immune checkpoint inhibitor therapy.”
New Blood-Based RNA Platform for Early Lung Cancer Diagnosis
“Blood-based methods utilizing circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA) are currently being developed to enable early and minimally invasive detection of lung cancer. However, these methods have demonstrated suboptimal performance in detecting cancers at the earliest stages (stages 0-II).”
Researchers explore the possibility of treating lung cancer by targeting telomeres
“Healthy cells can only divide a limited number of times during an organism’s lifetime. In contrast, tumor cells are immortal: they proliferate indefinitely and uncontrollably, and this is the defining characteristic of cancer.”
Videos:
Measuring Risk Factors of Developing SCLC
“Qian Wang, MD, MPH, assistant professor at Case Western Reserve University, thoracic oncologist at University Hospital Siteman Cancer Center, discusses the relevant metrics to determine the risk factor of developing small cell lung cancer (SCLC).”
AAPI community at higher risk of lung cancer
“Dr. Jeff Velotta of Kaiser Permanente discusses the heightened lung cancer risks for the Asian American Pacific Islander community.”
Panagis Galiatsatos, MD: Evolving Screening Strategies for Lung Cancer
“Lung cancer presents unique challenges in terms of treatment and control, as the spread of the disease significantly impacts patient outcomes. According to a session featured at the American Thoracic Society (ATS) 2023 International Conference in Washington, DC, the approach to screening for lung cancer has evolved.”
